GSK plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Luke Victor Miels
- Full Time Employees
- 66,841
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 79 New Oxford Street London GL United Kingdom WC1A 1DG
- IPO Date
- May 22, 1972
- Website
- gsk.com
- Similar Companies
- Business
- GSK plc operates as a global biopharmaceutical leader, dedicated to the research, development, and delivery of innovative medicines and vaccines across international markets. The company, which traces its origins back to 1715, refocused its strategy in July 2022 by spinning off its Consumer Healthcare division to form Haleon plc, thereby concentrating exclusively on its biopharma pipeline. Its operations are structured around key product areas: Specialty Medicines, Vaccines, and General Medicines. Within Specialty Medicines, GSK develops treatments for significant health challenges including HIV, oncology, respiratory conditions, and immuno-inflammatory diseases such as lupus. The Vaccines portfolio encompasses a broad range, preventing illnesses like shingles (Shingrix), meningitis, and respiratory syncytial virus (RSV) with its Arexvy vaccine. General Medicines typically address primary care needs, including inhalers for asthma and COPD, and various antibiotics. GSK generates revenue through the sale of these prescription products and vaccines to healthcare providers, hospitals, pharmacies, and governmental bodies worldwide. The company is strategically prioritizing investment in its innovative pipeline, anticipating at least twelve major product launches from 2025 in areas like infectious diseases, HIV, oncology, and respiratory health, reinforcing its commitment to scientific advancement. Recent corporate activities include strategic acquisitions such as Tesaro to bolster its oncology presence, and alliances with partners like CureVac for mRNA vaccine development. Headquartered in Brentford, United Kingdom, GSK aims to positively impact the health of 2.5 billion people by the end of the decade, driven by its purpose to unite science, technology, and talent to get ahead of disease. The company was formerly known as GlaxoSmithKline plc and adopted its current name, GSK plc, in May 2022.
Company News
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
Jefferies backs GSK with 2,500p target after positive lung cancer drug results
GSK lung cancer drug shows 61% response rate in early global trial
Contrasting GSK (NYSE:GSK) and United-Guardian (NASDAQ:UG)
GSK: Maintaining Strong Buy For LAI HIV Sales Growth And Further Oncology Expansion
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Is the Options Market Predicting a Spike in GSK Plc Stock?
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs
Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
GSK: The Gas Pedal Is Finally Down
Contrasting Eyepoint Pharmaceuticals (NASDAQ:EYPT) & GSK (NYSE:GSK)
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development